Source: Breast cancer. Unidade: FM
Subjects: NEOPLASIAS MAMÁRIAS, ANTINEOPLÁSICOS, EVENTO ADVERSO A MEDICAMENTO, BRASIL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTANA, Iuri A. et al. Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting. Breast cancer, v. 23, n. 2, p. 261-265, 2016Tradução . . Disponível em: http://link.springer.com/article/10.1007%2Fs12282-014-0564-9. Acesso em: 21 out. 2024.APA
Santana, I. A., Oliveira, J. A., Lima, J. M. da S., Testa, L., Piato, J. R. M., Hoff, P. M., & Mano, M. S. (2016). Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting. Breast cancer, 23( 2), 261-265. doi:10.1007/s12282-014-0564-9NLM
Santana IA, Oliveira JA, Lima JM da S, Testa L, Piato JRM, Hoff PM, Mano MS. Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting [Internet]. Breast cancer. 2016 ; 23( 2): 261-265.[citado 2024 out. 21 ] Available from: http://link.springer.com/article/10.1007%2Fs12282-014-0564-9Vancouver
Santana IA, Oliveira JA, Lima JM da S, Testa L, Piato JRM, Hoff PM, Mano MS. Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting [Internet]. Breast cancer. 2016 ; 23( 2): 261-265.[citado 2024 out. 21 ] Available from: http://link.springer.com/article/10.1007%2Fs12282-014-0564-9